The Burkitt Lymphoma International Prognostic Index Andrew M. Evens, DO, MSc Andrew M. Evens, DO, MBA, MSc Rutgers Cancer Institute #ASH20 #Lymphoma #Cancer #Research Link To Full Video: oncologytube.com/video/39713/an…

Our study evaluating prognostic factors driving Burkitt lymphoma outcome is out in this issue of @BloodJournal Thank you to all investigators for their contribution. Andrew M. Evens, DO, MBA, MSc Adam Olszewski MD ashpublications.org/blood/article/…

Thanks much 👏 Chan Cheah (and Kate Cwynarski, Graham Collins, Dr El-Galaly & many others) for collaborating on this work! It was great to combine International forces to analyze 1,000+ Burkitt #lymphoma patients and generate/validate this prognostication index (aka #BLIPI). #lymsm

Kudos to Brown University Rhode Island Hospital Adam & Adam (Adam Olszewski MD) on detailed #RWE analysis of CNS involvement in Burkitt #lymphoma. Several interesting nuggets of info gleaned (incidence, characteristics, outcomes, etc). Early View | Haematologica haematologica.org/article/view/h… #lymsm

Honored Jama Onc has published our work. Please get yourself vaccinated for those in whom it does not work. Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease ja.ma/3iCBPXS via JAMA Oncology part of JAMA Network

(2) Pts with #lymphoma have low responses to standard #CovidVaccine. + (2) CDC recommends #boosterdose for immunosuppressed = (4) If you had a CD20 antibody or are on active therapy for lymphoma, you're included. #lymsm ASH Lymphoma Research Foundation jamanetwork.com/journals/jamao…

The future of CLL therapy has arrived: our ph2 AVO trial in 1L CLL from Dana-Farber and BIDMC with support from AstraZeneca and Genentech is now online The Lancet Oncology authors.elsevier.com/a/1dlF45EIIgEB…

Defining and Treating High-grade B-cell #lymphoma, NOS | @BloodJournal ASH ashpublications.org/blood/article/… Happy to publish this review w/ Rhode Island Hospital Legorreta Cancer Center at Brown University Adam Olszewski MD & Dr Kurt on the challenging topic/entity of HGBL-NOS (1st pic below is correct Fig 1). #lymsm

We detected clonotypic DNA in the CSF of 36% #DLBCL pts @ high CNS relapse risk. (+)CSF = 29% risk of CNS relapse, (-)CSF assay = 0% risk. If validated - maybe a new way to help personalize CNS prophylaxis? doi.org/10.1182/blooda… #lymsm Blood Advances Adaptive Biotech Brown Hematology

Register at bit.ly/3GWO3nN to hear the latest research & info on aggressive #lymphoma from Dr. David Scott, Adam Olszewski MD, Dr. Neha Mehta-Shah & Dr. Dan Landsburg at #IUCLS2022! Join us live in Chicago April 29-30! UChicago CME

#boosters work for >50% of pts with #lymphoma who did not respond to initial vaccine. On or off treatment. Boosters + #Evusheld have largely eliminated #COVID deaths (in our center) #lymsm ACS Journal Cancer ASH doi.org/10.1002/cncr.3…

#COVID19 booster vaccination leads to seroconversion in over 1/2 of patients w/ hematologic malignancies who had undetectable antibodies to the initial vaccine series. The risk of death appears highest in those with undetectable antibodies. acsjournals.onlinelibrary.wiley.com/doi/full/10.10… OncoAlert

Defining and treating high-grade B-cell #lymphoma, NOS ashpublications.org/blood/article/… TY to The Warren Alpert Medical School Adam Olszewski MD & Brown University Dr Kurt collab on this review. 2 new classifications out since this was pre-published ~1 year ago but most content still valid/relevant! #lymsm

Editorial: The demise of Roe v Wade: a hematologist’s perspective loom.ly/MkH8V3g

East coast friends! John P. Leonard, MD gave Adam Olszewski MD and I the challenge of debating the utility of CNS prophylaxis in DLBCL. Come learn and watch us duke it out on 04/13 in NYC! Register now: okt.to/7oIirY Great Debates #bloodcancer #HematologicMalignancies

Check out our study on function, treatment, and outcomes in nursing home patients w/ DLBCL- a population very challenging to manage! Glad to see this published. This concludes a series of projects on older pts w/ aggressive lymphoma that are very close to my heart! Adam Olszewski MD

🙌TY to all collaborators (@sairah__ahmed, Loretta J. Nastoupil, MD, Uroosa Ibrahim, Narendranath Epperla, MD, MS, FACP, Timothy Voorhees, MD, MSCR, Adam Olszewski MD etc) & Rutgers Cancer Institute fellow Dr McKenna on this #RWE of #CART for rel/ref SOT-PTLD. We describe immunosupression, toxicity & outcomes. British Journal of Haematology onlinelibrary.wiley.com/doi/10.1111/bj…

For systemic #CTCL /MF/SS, Brown Hematology we choose #immunotherapy a lot. Reviewing T-cell containment options: kill'em, poison'em, PD1-knock'em. But really we should be turning them against each other... ncbi.nlm.nih.gov/pmc/articles/P… Tom Ollila #lymsm

Delighted to share our work now published on behalf of all co-authors. Our practice has changed- minimal use of HD-MTX in CNS prophylaxis in aNHL. Thank you so much to all international collaborators! ascopubs.org/doi/10.1200/JC…

New: Final results from the phase 3 HOVON/SAKK trial, comparing R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma thelancet.com/journals/lanha…